Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis
نویسندگان
چکیده
Objectives To evaluate the effect of Atorvastatin as an adjuvant with betamethasone valerate on disease severity and cardiovascular risks in chronic plaque type psoriatic patients. Methods It is an interventional study conducted in Pharmacology Department of BMSI, JPMC with the collaboration of Dermatology Department of JPMC, Karachi. The duration of study was from June 2013 to June 2016. Seventy five psoriatic patients were prescribed Tablet Atorvastatin 40-20 mg/day (40mg for first three months twice daily followed by 20mg once daily for the next three month) plus topical Betamethasone Valerate 0.1% once daily for 6 months (three week apply than one week interval). The efficacy and safety profile of drugs was measured by PASI, DLQI, hsCRP, LFTS and Lipid profile. Results The percentage change of PASI is 86.749±0.547, DLQI is 82.697±.2.61 and hsCRP is 40.371±8.505, which showed highly significant improvement in patient at the end of last follow up. LFTs and CPK for safety profile of therapy showed non-significant results. Conclusion Atorvastatin used as an adjuvant therapy with currently existing standard therapy (topical betamethasone) in patients having mild to moderate plaque type psoriasis reduces disease severity and cardiovascular risks.
منابع مشابه
Improvement of inflammatory dermatoses severity and quality of life in patients treated with a betamethasone valerate plaster (LIBERE study)
BACKGROUND A ready to use betamethasone valerate 0.1% (BMV) dressing was effective and well-tolerated by patients receiving chronic plaque psoriasis treatment. OBJECTIVE Collect data related to BMV dressing used in the context of market authorization. METHODS An observational, prospective study, including 258 patients with a maximum 4-weeks-treatment of inflammatory dermatosis with BMV 2.25...
متن کاملBetamethasone valerate dressing is non-inferior to calcipotriol–betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial
BACKGROUND A ready-to-use betamethasone valerate 0.1% (BMV) dressing was found to be superior to placebo dressing and a reference 0.1% BMV cream in the treatment of patients with chronic plaque psoriasis (CPP). METHODS This multicentre, prospective, randomized, investigator-blinded, controlled, non-inferiority trial compared the efficacy and safety of the BMV dressing to the calcipotriol-beta...
متن کاملBetamethasone valerate foam: a look at the clinical data
Topical corticosteroids and especially betamethasone valerate (BMV) have been used topically to relieve many inflammatory skin conditions such as psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs can influence the performance of these topical applications. BMV has traditionally been available in creams, ointments, lotions and sprays. In the early 2000s, a topical hydroe...
متن کاملComparative Study of Efficacy of Various Topical Treatment Modalities for Psoriasis
Aim of the study : To compare the efficacy and tolerability of various topical therapies like short contact Lipsomal dithranol ointment, 0.1% Betamethasone valerate ointment and liquid paraffin for psoriasis. Materials and Methods: This study was conducted in dermatology department of a tertiary hospital and a total of sixty patients who attended the Psoriasis clinic were randomly allocated to ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 33 شماره
صفحات -
تاریخ انتشار 2017